EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Information resources and Schedules

European Regulations

www.ema.europa.eu

Presented by: Dr Agnes Saint Raymond
Human Medicines Special Areas 17 Oct 2012

Information on vaccines

Regulation No (EC) 726/2004 amended by

- The Paediatric Regulation (EC) No 1901/2006
- The Pharmacovigilance Regulation (EU) No 1235/2010
- Article 57 (1.l) on 'Eudrapharm'

"creating a **database** on medicinal products, to be accessible to the general **public**, and ensuring that it is updated, and managed independently of pharmaceutical companies; the database shall facilitate the search for information already authorised for package leaflets; it shall include a section on medicinal products authorised for the treatment of **children**; the information provided to the public shall be worded in an appropriate and comprehensible manner;"

Article 1(13.b), amending article 57

"For the purpose of the database, the Agency shall set up and maintain a **list** of all medicinal products for human use authorised in the Union. To this effect, the following measures shall be taken:

(a) the Agency shall by 2 July 2011 at the latest make public a **format for the electronic** submission of information on medicinal products for human use;

(b) MAHs shall by **2 July 2012** at the latest, electronically submit to the Agency information on all medicinal products for human use authorised or registered in the Union, using the format referred to in point (a)

© From the date set out in point (b) MAHs shall inform the Agency of any new or varied marketing authorisations granted in the Union, using the format referred to in point (a)"

Data available to the Agency - 1/2

- Product invented Name and Marketing Authorisation Holder
- Active substance (… adjuvant if any)
- Dose, route of administration, pack size
- Therapeutic area (ATC code) and indication (MedDRA code)
- MA status (date, renewal, withdrawals..)
- Summary of Product Characteristics (electronic version)

Data available to the Agency - 2/2

No one knows how many 'products' in the EU

600,000 in total?

Currently, submission of about 254,000 'products' including paediatric vaccines

but

- **Information still being submitted**
- **Compliance with obligation not checked**
- **Data not validated (duplicates, etc)**

Vaccines information (as of 9 Oct.)

301 vaccines for childhood immunisation, combined or not:

- Diphteria, Tetanos, Pertussis, Polio
- Haemophilus influenza B, Meningococcus, Pneumococcus, Typhoid
- Measles, Mumps, Rubella, Varicella, Rotavirus
- Hepatitis B, Papilloma
- Influenza
- Tuberculosis

Marketing Authorisation Holders for these vaccines

Baxter

Novartis

Sanofi-Pasteur-MSD, Merck

Medac Gesellschaft

Organon

GSK vaccines ongoing

Public information?

Not yet available considering the need for quality data and amount of data

'Roadmap' to be drafted on what information, which format and by when.

Getting the best schedules right!

Defining the best schedules?

Paediatric Regulation (EC) No 1901/2006 in force since 2007

Requires agreement of Paediatric Investigation Plans for any new medicinal product (or new indication, route, form) to be authorised EITHER nationally or centrally

Agreement by expert Paediatric Committee at EMA

MANDATORY for vaccines: both the plan and compliance with the plan

Paediatric Investigation Plans

Data on efficacy, safety and quality (formulation, dosage form), Timelines (ref ICH guideline E11)

In practice, discussion on potential paediatric use and unmet needs to decide on the development and formulation for each age group, from birth to 18 years



Life cycle of a medicine from EMA perspective



Paediatric Committee Workload

	2008	2009	2010	2011	2012	Total
Applications (indications)	271 (395)	273 (395)	326 (403)	187 (220)	138 (165)	*1195 (1578)*
Opinions on PIP/Waivers	133	202	260	155	100	*850*
Modifications	8	51	107	155	126	*447*

Sept 2012

Paediatric Investigation plans for vaccines

Flu Seasonal: 7 - H1N1 and prepandemic: 4

HPV vaccine: 4

Meningo: 3

Hep B: 1

Rotavirus:1

Pneumo: 1

DTPP: 1

Japanese encephalitis: 1 Smallpox:1

Content of a Paediatric Investigation Plan

Quality, safety and efficacy data necessary to support a paediatric indication, with appropriate formulation and form

In practice clinical trials required for authorisation have to be defined (design, primary endpoint and 2-3 main secondary, inclusion criteria, duration, control or comparator(s), sample size)

Compliance is checked and lack of compliance prevents validation of the application for MA.

Unnecessary Paediatric Clinical Trials are unethical

Clinical trials should only be performed to answer a scientific question whose answer is unknown

Exposing children in unnecessary trials is unethical

Currently, children are included in multiple trials (up to 40!) for the purpose of studying multiple vaccine schedules

The Paediatric Committee has to require trials for the best schedule(s)

The EMA Paediatric Committee needs your help

- To define the best 2-3 schedules covering the needs of all Member States ('bracketing'?)
- Without multiplying the trials unnecessarily

- *PDCO would like to get guidance from Member States on the schedules should be included in the Paediatric Investigation Plans*
- *Work could be coordinated by ECDC and the European Commission?*

CONCLUSIONS

- Information on products authorised in the EU will be available (with caveats)
- Unique opportunity to progress understanding of vaccines schedules
- Request for help from Member States to identify the 'best schedules' to simplify and optimise the development of vaccines to guide Paediatric Committee
- Avoid unnecessary unethical trials with children!